

Online Data Supplement

***LTA4H* association to montelukast response in early and late-onset asthma**

Cyrielle Maroteau^{1,2}, Antonio Espuela-Ortiz³, Esther Herrera-Luis³, Sundararajan Srinivasan², Fiona Carr², Roger Tavendale², Karen Wilson², Natalia Hernandez-Pacheco^{2,4}, James Chalmers⁵, Steve Turner⁶, Somnath Mukhopadhyay⁷, Anke H Maitland-van der Zee^{8,9,10}, Esteban G. Burchard^{11,12}, Maria Pino-Yanes^{3,13,14}, Simon Young¹⁴, Glenda Lassi¹, Adam Platt¹⁶, Colin N A Palmer² on behalf of the PiCA consortium

Contents

Use of *LTA4H* rs2660845 variant as dominant

Association between rs2660845 and asthma exacerbation in non-montelukast users

Table E1

Table E2

Table E3

Table E4

Table E5

Table E6

Figure E1

Figure E2

References

Use of *LTA4H* rs2660845 variant as dominant

The association between the genotype and exacerbation status under montelukast treatment has been presented as an additive and dominant model in two other publications (respectively (E1, E2)). The sub-additivity of the effect is observed there. The use of a dominant model slightly underweights the effect of individuals homozygous for the minor allele; however, in order to perform a case-control analysis on small-sized cohorts we were under-powered to detect meaningful effects in the rare homozygotes. Moreover, the collapsing of the rare allele into a “carriers vs. non-carrier” group is common practice in order to reduce the volatility of small cell sizes in case control analyses.

Association between rs2660845 and asthma exacerbation in non-montelukast users

To verify the effect of rs2660845 on montelukast response and not just on exacerbation, we tested the association between rs2660845 and exacerbation in non-montelukast users. In late-onset, as we have longitudinal data for GoSHARE(a) cohort, individuals previously selected as being under montelukast treatment were used. The binary effect of experiencing an exacerbation was defined a year before start of therapy. In early-onset asthma, genetic data from non-montelukast users were only available from PAGES, BREATHE GALA and SAGE cohorts. Individuals were selected as not being under montelukast treatment at enrolment. The binary risk of having an asthma exacerbation was defined as 0 = no exacerbation, 1 = at least one exacerbation event, in a time frame of 6 to 12 months. An asthma exacerbation was defined as:

For PAGES and BREATHE, at least one of the following in the previous 6 months: hospital admission, course of oral corticosteroids (OCS) and absence from school due to asthma symptoms.

For GoSHARE (a), at least one of the following within a year before first montelukast prescription date: hospital admission, emergency room visit, course of OCS and discontinuation of the drug. Study details are presented in *Table E3*.

Statistical analyses were performed in SAS 9.3 (SAS Institute, Cary, NC, USA). Binary logistic regression model was used to test the association between rs2660845 and the binary risk of having an exacerbation. LTA4H variant effect was considered dominant and p value (P) less than 0.05 was considered significant. Results for late-onset and early-onset are presented in respectively *Table E4 and E5*.

Table E1. Power of the sample size for combined cohorts to detect increases in OR for asthma exacerbation.

GoSHARE (a) is the late-onset population (>18 years-old)

GoSHARE (b) is the early-onset population (<= 18 years-old)

Asthma onset	Ethnicity	Cohort	OR=1.2	OR=1.5	OR=3
Late	Europeans	UKBiobank, GoSHARE (a)	82%	99%	100%
Early	Europeans	GoSHARE (b), BREATHE, Tayside RCT, PAGES	31%	86%	100%
Early	Europeans, African Americans, Hispanics/Latinos	GoSHARE (b), BREATHE, Tayside RCT, PAGES, SAGE, GALA II	64%	97%	100%

Table E2. Selection of asthmatic patients in GoSHARE by treatment steps.

Steps	Medication	Number of GoSHARE patients (n)
1	SABA as needed	10,218
2	SABA as needed +ICS	5,388
3	SABA as needed + ICS + LABA	4,551
4	SABA as needed + LTRA (+ICS +LABA)	1,070

Step 1: inhaled short-acting β 2-agonists (SABA) on demand;

Step 2: regular inhaled steroids (ICS) plus SABA on demand;

Step 3: regular inhaled long-acting β 2-agonists (LABA) (salmeterol or formoterol) plus ICS with SABA on demand;

Step 4: oral montelukast with SABA on demand (plus ICS plus/or regular LABA).

Table E3. Covariates association with asthma exacerbation binary trait.

*Traits with a P <0.05 were used as covariates in the logistic regression.

For GALA II and SAGE, betas 95%(CI) are reported for quantitative variables

	Odds ratio (95%CI) for exacerbation; P-value						Betas (95%CI) for exacerbation; P-value	
	UKBiobank N=1,561	GoSHARE (a) N=953	GoSHARE (b) N=88	BREATHE N=210	Tayside RCT N=62	PAGES N=163	GALA II N=486	SAGE N=71
Gender (M vs F)	1.07 (0.78-1.46) P=0.66	1.18 (0.76-1.82) P=0.44	12.9(2.10-79) P=0.006*	1.04 (0.81-1.34) P=0.74	0.97 (0.31-2.71) P=0.89	1.99 (1.02-3.9); P=0.04*	1.16 (0.75-1.81) P=0.494	2.39 (0.74-7.76) P=0.1465
Age at 1st LTRA	-	1.01 (1.003-1.03) P=0.013*	1.14(0.89-1.45) P=0.29	-	-	-	-	-
Age at 1st SABA	-	1.01 (0.99-1.02) P=0.18	0.79 (0.56-1.09) P=0.15	-	-	-	-	-
Exacerbation before 1st LTRA	1.4 (1.02-1.92) P<0.036*	6.02 (3.91-9.26) P<0.0001*	8.91 (5.99-13.2) P<0.0001*	-	-	-	-	-
Age at recruitment	-	-	-	0.86 (0.83-0.89) P<0.0001*	1.11 (0.96-1.29) P=0.14	0.93 (0.84-1.02) P=0.16	0.03 (-0.01-0.07) P=0.453	-0.07 ((-0.02) – (-0.18)) P=0.476
BMI	-	-	-	0.95 (0.92-0.98) P=0.0035*	1.07 (0.94-1.22) P=0.24	0.97 (0.91-1.05) P=0.54	-	-
Age of asthma onset	1.06 (1.02-1.09) P=0.0003*	-	-	-	-	-	-0.07 [-0.10- (-0.03)] P=0.052*	-0.06 ((-0.25)-0.14) P=0.5756
PC1	-	-	-	-	-	-	47.87 [-55.85-(-39.89)] P<0.0001*	19.24 ((-6.85)-45.32) P=0.148
PC2	-	-	-	-	-	-	5.28 (-2.14-12.71) P=0.476	-0.60 ((-29.23)- 28.03) P=0.967

Table E4. Details of late-onset and early-onset in three non-montelukast user populations.¹Exacerbation within 6 months; ²Exacerbation within 12 months

OCS: Oral Corticosteroids

ER: Emergency Room visit

GoSHARE (a) is the late-onset population (>18 years-old)

GoSHARE (b) is the early-onset population (<= 18 years-old)

	GoSHARE (a)	GoSHARE (b)	BREATHE	PAGES
N	953	88	94	356
% male (n)	44	21	57	56
Mean age (SD) years	40 (16)	9 (5)	10 (3.6)	10 (3.5)
Study type	longitudinal	longitudinal	Cross-sectional	Cross-sectional
Exacerbation in 6-12 month	OCS, hospitalisation, ER ²	OCS, hospitalisation, ER ²	OCS, hospitalisation, school absence ¹	OCS, hospitalisation, school absence ¹
Exacerbation (%)	19	12	36	61
rs2660845 G variant frequency	0.27	0.27	0.27	0.26

Table E5. Details of early-onset asthma adult montelukast user from the UKBiobank.

¹Exacerbation within 6 months; ²Exacerbation within 12 months

OCS: Oral Corticosteroids

ER: Emergency Room visit

Patients were diagnosed as having early-onset asthma.

Montelukast prescription records were only available as adults.

	UKBiobank
N	511
% male (n)	34
Mean age (SD) years	10 (4)
Study type	longitudinal
Exacerbation in 6-12 month	OCS, hospitalisation, ER ²
Exacerbation (%)	21
rs2660845 G variant frequency	0.27

Table E6. Association between rs2660845 and asthma exacerbation in early-onset UKBiobank individuals a year after taking montelukast prescription as adults.

Patients were diagnosed as having early-onset asthma.

Montelukast prescription records were only available as adults.

Study	UKBiobank (n=511)
OR (95% CI)	1.34 (0.82-2.19)
P-value	0.23

Table E7. Cis-eQTL effect of rs2660845 on *LTA4H* expression in whole blood from adult cohorts.

BIOSQTL: The Biobank-Based Integrative Omics Study Quantitative Trait Locus (E3)

eQTLGen: expression Quantitative Trait Loci Genetic (E4)

Consortium	P-value	rsID	Chr	Position(hg19)	ID	Gene symbol	Z-score	Assessed	Other	Number of cohorts	Number of samples	FDR
BIOSQTL	6.27E-08	rs2660845	12	96438553	ENSG00000111144,ENSG00000257878	LTA4H	-5.41	G	A	4	2116	0
eQTLGen	4.89E-07	rs2660845	12	96438553	ENSG00000111144	LTA4H	-5.03	G	A	37	31683	0.0016

FDR: False Discovery Rate

ID: Gencode Identifier




Figure E1. Age (a) and ethnicity (b) distributions in the GTEx portal (V8, (E5))




Figure E2. Box plot showing the *cis*-eQTL effect of rs2660845 on *LTA₄H* expression in whole blood (beta=-0.020, P-value=0.46). (GTEx v8, (E5))

References

- E1. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. *American journal of respiratory and critical care medicine* 2006; 173: 379-385.
- E2. Kotani H, Kishi R, Mouri A, Sashio T, Shindo J, Shiraki A, Hiramatsu T, Iwata S, Taniguchi H, Nishiyama O. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma. *Journal of clinical pharmacy and therapeutics* 2012; 37: 112-116.
- E3. Zhernakova DV, Deelen P, Vermaat M, Van Iterson M, Van Galen M, Arindrarto W, Van't Hof P, Mei H, Van Dijk F, Westra H-J. Identification of context-dependent expression quantitative trait loci in whole blood. 2017; 49: 139.
- E4. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreuzhuber R, Kasela SJB. Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis. 2018: 447367.
- E5. Consortium GT. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 2015; 348: 648-660.